Drug intelligence / Profile preview

URLC10 peptides

Development stage: Unknown
Lead developer: Shiga University
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

URLC10 peptides are cancer vaccine peptides derived from the URLC10 antigen (up-regulated in lung and esophageal cancers 10). These peptides are designed to stimulate cytotoxic T lymphocyte (CTL) responses against URLC10-expressing tumor cells. They are typically administered subcutaneously and have been investigated in clinical trials for advanced gastric cancer and non-small cell lung cancer. The peptides are HLA-restricted, meaning they are designed to work with specific human leukocyte antigen (HLA) types.

Other names: HLA-A*2402-restricted URLC10 peptidesHLA-A*0201-restricted URLC10 peptidesURLC10-A24-177URLC-10-A24-177URLC 10-A24-177

Targets

URLC10/HLA-A*24:02 (URLC10 peptide-HLA-A*24:02 complex)

Beyond the preview

Go deeper on URLC10 peptides.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on URLC10 peptides.

Explore the full profile